Jimmy Orjala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jimmy Orjala has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
Aleksej Krunic
Department of Pharmaceutical Sciences
27 shared publicationsSteven M. Swanson
Department of Medicinal Chemistry and Pharmacognosy , University of Illinois at Chicago , Chicago , Illinois 60612 , United States
11 shared publicationsHahk-Soo Kang
Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, 833 S. Wood Street, Chicago, IL 60612, United States
8 shared publications- Camila Manoel Crnkovic
Faculdade de Ciências Farmacêuticas Universidade de São Paulo São Paulo Brazil
7 shared publications Shunyan Mo
7 shared publications- Alessandra S. Eustaquio
Department of Pharmaceutical Sciences, Retzky College of Pharmacy, University of Illinois Chicago
6 shared publications
Latest Publications
- Open Access
- 28 April 2026
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 89 (5) , 1597-1609
The Human Gut Microbiome Metabolizes Diverse Bioactive Coumarins via α,β-Unsaturated Lactone Reduction
The gut microbiome can influence drug efficacy through the direct metabolism of bioactive molecules. Despite numerous high-throughput screens for drug-microbiome interactions, the gut microbial metabolism of many bioactive compounds and its impact on treatment efficacy remain uncharacterized. We chose to investigate coumarins, which are a large class of bioactive natural products and chemical scaffolds for synthetic drugs. The core of the class, 1,2-benzopyrone, is metabolized by the microbiome to yield 3,4-dihydrocoumarin and melilotic acid via α,β-unsaturated lactone reduction. To explore the scope of this pathway, we screened a structurally diverse group of 12 bioactive coumarins using semitargeted LC-MS/MS metabolomics and ex vivo cultures of human feces. The culturable gut microbiome can reduce the α,β-unsaturated lactone of isocoumarin, simple, furano, pyrano, and prenylated coumarins with an unsubstituted 3,4-alkene bond. In a monoculture screen of microbiome isolates, we determined that 11 species could metabolize multiple coumarins through this pathway. Further, we demonstrate the direct coumarin-reducing capability of N-ethylmaleimide reductase from Escherichia coli. Finally, gut microbial metabolites of methoxsalen had diminished cytotoxicity against melanoma cancer cells compared to the parent drug. In summary, the human gut microbiome utilizes a single metabolic pathway to modulate the bioactivities of many coumarins.
- 28 April 2026
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 89 (5) , 1597-1609
Open AccessThe Human Gut Microbiome Metabolizes Diverse Bioactive Coumarins via α,β-Unsaturated Lactone Reduction
The gut microbiome can influence drug efficacy through the direct metabolism of bioactive molecules. Despite numerous high-throughput screens for drug-microbiome interactions, the gut microbial metabolism of many bioactive compounds and its impact on treatment efficacy remain uncharacterized. We chose to investigate coumarins, which are a large class of bioactive natural products and chemical scaffolds for synthetic drugs. The core of the class, 1,2-benzopyrone, is metabolized by the microbiome to yield 3,4-dihydrocoumarin and melilotic acid via α,β-unsaturated lactone reduction. To explore the scope of this pathway, we screened a structurally diverse group of 12 bioactive coumarins using semitargeted LC-MS/MS metabolomics and ex vivo cultures of human feces. The culturable gut microbiome can reduce the α,β-unsaturated lactone of isocoumarin, simple, furano, pyrano, and prenylated coumarins with an unsubstituted 3,4-alkene bond. In a monoculture screen of microbiome isolates, we determined that 11 species could metabolize multiple coumarins through this pathway. Further, we demonstrate the direct coumarin-reducing capability of N-ethylmaleimide reductase from Escherichia coli. Finally, gut microbial metabolites of methoxsalen had diminished cytotoxicity against melanoma cancer cells compared to the parent drug. In summary, the human gut microbiome utilizes a single metabolic pathway to modulate the bioactivities of many coumarins.
- Open Access
- 21 January 2026
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 89 (2) , 573-583
Discovery of Suomilide and Cyanopeptolin Analogues by 15 N Stable Isotope Labeling and Genome Mining of Cyanobacteria
Cyanobacteria have been a promising source for natural product drug discovery for decades using mainly activity-guided approaches. More recently, genome mining and bioinformatics-guided approaches have become increasingly utilized in bacterial drug discovery and have proven to be successful in revealing novel metabolites predicted by biosynthetic gene clusters. However, detection and identification of these predicted metabolites can be difficult. Connecting nitrogen-containing natural products with the corresponding gene clusters encoding them in cyanobacteria can be aided by cyanobacteria's ability to incorporate inorganic nitrogen into their secondary metabolites. Feeding cyanobacteria with 15N-labeled and 14N nitrate and comparing the resulting metabolic profiles via mass spectrometry allows for the identification of nitrogen-containing metabolites, which can then be connected to biosynthetic gene clusters. Investigation of Nostoc sp. UIC 10890 using this workflow identified 28 total gene clusters and five groups of masses incorporating 15N-labeled nitrogen. Two of these groups contained new compounds, and the structures were elucidated by NMR and MS/MS. Three new compounds suomilide F, cyanopeptolin UIC949, and cyanopeptolin UIC999 were shown to have inhibitory activity against different serine proteases.
- 21 January 2026
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 89 (2) , 573-583
Open AccessDiscovery of Suomilide and Cyanopeptolin Analogues by 15 N Stable Isotope Labeling and Genome Mining of Cyanobacteria
Cyanobacteria have been a promising source for natural product drug discovery for decades using mainly activity-guided approaches. More recently, genome mining and bioinformatics-guided approaches have become increasingly utilized in bacterial drug discovery and have proven to be successful in revealing novel metabolites predicted by biosynthetic gene clusters. However, detection and identification of these predicted metabolites can be difficult. Connecting nitrogen-containing natural products with the corresponding gene clusters encoding them in cyanobacteria can be aided by cyanobacteria's ability to incorporate inorganic nitrogen into their secondary metabolites. Feeding cyanobacteria with 15N-labeled and 14N nitrate and comparing the resulting metabolic profiles via mass spectrometry allows for the identification of nitrogen-containing metabolites, which can then be connected to biosynthetic gene clusters. Investigation of Nostoc sp. UIC 10890 using this workflow identified 28 total gene clusters and five groups of masses incorporating 15N-labeled nitrogen. Two of these groups contained new compounds, and the structures were elucidated by NMR and MS/MS. Three new compounds suomilide F, cyanopeptolin UIC949, and cyanopeptolin UIC999 were shown to have inhibitory activity against different serine proteases.
- Open Access
- 2 December 2025
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 88 (12) , 2968-2977
Beyond Monomers: Discovery of Bioactive Naphthoquinone Heterodimers and Perenniporides from Pyrenochaetopsis Species
Naphthoquinones can be found in Nature in various formats, both as standalone molecules and as building blocks for larger structures. A study of the fungus, Pyrenochaetopsis sp. (strain MSX63699), led to the isolation of naphthoquinone analogues (1-21), including both monomers and heterodimers and seven new compounds─three kirschsteinin analogues (11-13) and four perenniporides (18-21). The structures of these were elucidated through analysis of data from 1D and 2D NMR, HRESIMS, and ECD experiments, and several compounds displayed cytotoxic activity against melanoma (MDA-MB-435) and ovarian (OVCAR3) cancer cell lines, with structure-activity trends suggesting key roles for specific substituents in enhancing bioactivity. Notably, compounds 3-6, 9, 11, 15, and 19-20 had IC50 values that ranged from about 1 to 5 μM against both cell lines. Overall, this work expands the chemical diversity of fungal naphthoquinones by identifying new heterodimeric and perenniporide-type analogues and underscores the untapped biosynthetic potential of the Pyrenochaetopsis species.
- 2 December 2025
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 88 (12) , 2968-2977
Open AccessBeyond Monomers: Discovery of Bioactive Naphthoquinone Heterodimers and Perenniporides from Pyrenochaetopsis Species
Naphthoquinones can be found in Nature in various formats, both as standalone molecules and as building blocks for larger structures. A study of the fungus, Pyrenochaetopsis sp. (strain MSX63699), led to the isolation of naphthoquinone analogues (1-21), including both monomers and heterodimers and seven new compounds─three kirschsteinin analogues (11-13) and four perenniporides (18-21). The structures of these were elucidated through analysis of data from 1D and 2D NMR, HRESIMS, and ECD experiments, and several compounds displayed cytotoxic activity against melanoma (MDA-MB-435) and ovarian (OVCAR3) cancer cell lines, with structure-activity trends suggesting key roles for specific substituents in enhancing bioactivity. Notably, compounds 3-6, 9, 11, 15, and 19-20 had IC50 values that ranged from about 1 to 5 μM against both cell lines. Overall, this work expands the chemical diversity of fungal naphthoquinones by identifying new heterodimeric and perenniporide-type analogues and underscores the untapped biosynthetic potential of the Pyrenochaetopsis species.
- Open Access
- 15 July 2025
- Published by Royal Society of Chemistry (RSC) in Natural Product Reports
- Vol. 43 (2) , 286-300
Green genes from blue greens: challenges and solutions to unlocking the potential of cyanobacteria in drug discovery
Cyanobacteria are prolific producers of bioactive natural products. In this article, we outline some challenges faced in exploiting cyanobacteria for drug discovery, current solutions, and pathways forward to fully explore them for drug discovery.
- 15 July 2025
- Published by Royal Society of Chemistry (RSC) in Natural Product Reports
- Vol. 43 (2) , 286-300
Open AccessGreen genes from blue greens: challenges and solutions to unlocking the potential of cyanobacteria in drug discovery
Cyanobacteria are prolific producers of bioactive natural products. In this article, we outline some challenges faced in exploiting cyanobacteria for drug discovery, current solutions, and pathways forward to fully explore them for drug discovery.
- 20 February 2025
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 88 (3) , 732-746
Menominin A and B: Cytotoxic Cyclodepsipeptides from the Freshwater Sponge-Associated Cyanobacterium Nostoc sp. UIC 10607
Menominin A (1) and B (2), two cyclodepsipeptides containing a 3,8-dihydroxy-2-methyltetradecanoic acid residue, were isolated from the freshwater sponge-associated cyanobacterium, Nostoc sp. UIC 10607, using bioactivity-guided and spectroscopic approaches. The planar structures of 1 and 2 were established using HRESIMS and one- and two-dimensional NMR experiments. Comparative genomic analysis revealed unique differences in the putative menominin biosynthetic gene cluster compared to that of the closely related cyanobacterial cyclic lipodepsipeptide, hapalosin, assisting in structure elucidation and highlighting the structural diversity of this class of compounds. Configuration assignments were determined using a combination of J-based configuration analysis, chiral HPLC, modified Mosher's ester analysis, and DFT calculations. Menominin A and B demonstrate antiproliferative bioactivity against the high-grade serous ovarian cancer cell line OVCAR3 (IC50 = 3.1 (1) and 2.4 μM (2)). Menominin A and B are the first reported secondary metabolites from a freshwater sponge-associated cyanobacterium, underscoring the potential of freshwater sponges as a microbial culture source in natural product discovery.
- 20 February 2025
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 88 (3) , 732-746
Menominin A and B: Cytotoxic Cyclodepsipeptides from the Freshwater Sponge-Associated Cyanobacterium Nostoc sp. UIC 10607
Menominin A (1) and B (2), two cyclodepsipeptides containing a 3,8-dihydroxy-2-methyltetradecanoic acid residue, were isolated from the freshwater sponge-associated cyanobacterium, Nostoc sp. UIC 10607, using bioactivity-guided and spectroscopic approaches. The planar structures of 1 and 2 were established using HRESIMS and one- and two-dimensional NMR experiments. Comparative genomic analysis revealed unique differences in the putative menominin biosynthetic gene cluster compared to that of the closely related cyanobacterial cyclic lipodepsipeptide, hapalosin, assisting in structure elucidation and highlighting the structural diversity of this class of compounds. Configuration assignments were determined using a combination of J-based configuration analysis, chiral HPLC, modified Mosher's ester analysis, and DFT calculations. Menominin A and B demonstrate antiproliferative bioactivity against the high-grade serous ovarian cancer cell line OVCAR3 (IC50 = 3.1 (1) and 2.4 μM (2)). Menominin A and B are the first reported secondary metabolites from a freshwater sponge-associated cyanobacterium, underscoring the potential of freshwater sponges as a microbial culture source in natural product discovery.
- 14 November 2024
- Published by Royal Society of Chemistry (RSC) in Natural Product Reports
- Vol. 42 (1) , 6-49
Chemical diversity of cyanobacterial natural products
This review article covers 995 natural products of cyanobacterial origin reported from 2010 to 2023. Compounds were analyzed using similarity networking to gain insights into their chemical diversity.
- 14 November 2024
- Published by Royal Society of Chemistry (RSC) in Natural Product Reports
- Vol. 42 (1) , 6-49
Chemical diversity of cyanobacterial natural products
This review article covers 995 natural products of cyanobacterial origin reported from 2010 to 2023. Compounds were analyzed using similarity networking to gain insights into their chemical diversity.
- 25 February 2022
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 85 (3) , 702-719
Discovery of Anticancer Agents of Diverse Natural Origin
Research progress from mainly over the last five years is described for a multidisciplinary collaborative program project directed toward the discovery of potential anticancer agents from a broad range of taxonomically defined organisms. Selected lead compounds with potential as new antitumor agents that are representative of considerable structural diversity have continued to be obtained from each of tropical plants, terrestrial and aquatic cyanobacteria, and filamentous fungi. Recently, a new focus has been on the investigation of the constituents of U.S. lichens and their fungal mycobionts. A medicinal chemistry and pharmacokinetics component of the project has optimized structurally selected lead natural products, leading to enhanced cytotoxic potencies against selected cancer cell lines. Biological testing has shown several compounds to have in vivo activity, and relevant preliminary structure–activity relationship and mechanism of action studies have been performed. Several promising lead compounds worthy of further investigation have been identified from the most recent collaborative work performed.
- 25 February 2022
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 85 (3) , 702-719
Discovery of Anticancer Agents of Diverse Natural Origin
Research progress from mainly over the last five years is described for a multidisciplinary collaborative program project directed toward the discovery of potential anticancer agents from a broad range of taxonomically defined organisms. Selected lead compounds with potential as new antitumor agents that are representative of considerable structural diversity have continued to be obtained from each of tropical plants, terrestrial and aquatic cyanobacteria, and filamentous fungi. Recently, a new focus has been on the investigation of the constituents of U.S. lichens and their fungal mycobionts. A medicinal chemistry and pharmacokinetics component of the project has optimized structurally selected lead natural products, leading to enhanced cytotoxic potencies against selected cancer cell lines. Biological testing has shown several compounds to have in vivo activity, and relevant preliminary structure–activity relationship and mechanism of action studies have been performed. Several promising lead compounds worthy of further investigation have been identified from the most recent collaborative work performed.
- 31 January 2022
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 85 (3) , 540-546
Aulosirazoles B and C from the Cyanobacterium Nostoc sp. UIC 10771: Analogues of an Isothiazolonaphthoquinone Scaffold that Activate Nuclear Transcription Factor FOXO3a in Ovarian Cancer Cells
The known solid-tumor-selective cytotoxin aulosirazole (1) was identified from bioactive extracts from the culture medium of the cyanobacterium Nostoc sp. UIC 10771. Here, we demonstrate that 1 induces the nuclear accumulation of FOXO3a in OVCAR3 using both Western blot analysis and immunofluorescence confocal microscopy. We also report the discovery of two additional analogues, aulosirazoles B (2) and C (3). Structures for compounds 2 and 3 were determined using HR-ESI-LC-MS/MS and 1D and 2D NMR experiments. Aulosirazoles B (2) and C (3) represent the first natural analogues of the FOXO-activating compound aulosirazole (1) and are the second and third isothiazole-containing metabolites reported from this phylum.
- 31 January 2022
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 85 (3) , 540-546
Aulosirazoles B and C from the Cyanobacterium Nostoc sp. UIC 10771: Analogues of an Isothiazolonaphthoquinone Scaffold that Activate Nuclear Transcription Factor FOXO3a in Ovarian Cancer Cells
The known solid-tumor-selective cytotoxin aulosirazole (1) was identified from bioactive extracts from the culture medium of the cyanobacterium Nostoc sp. UIC 10771. Here, we demonstrate that 1 induces the nuclear accumulation of FOXO3a in OVCAR3 using both Western blot analysis and immunofluorescence confocal microscopy. We also report the discovery of two additional analogues, aulosirazoles B (2) and C (3). Structures for compounds 2 and 3 were determined using HR-ESI-LC-MS/MS and 1D and 2D NMR experiments. Aulosirazoles B (2) and C (3) represent the first natural analogues of the FOXO-activating compound aulosirazole (1) and are the second and third isothiazole-containing metabolites reported from this phylum.
- 27 July 2021
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 84 (8) , 2256-2264
Phormidepistatin from the Cyanobacterium UIC 10484: Assessing the Phylogenetic Distribution of the Statine Pharmacophore
A new linear lipopeptide, phormidepistatin (1), containing an epi-statine amino acid was isolated from cf. Phormidium sp. strain UIC 10484. The planar structure was elucidated by 1D and 2D NMR experimentation. The relative configuration was determined by J-based configurational analysis and the absolute configuration by advanced Marfey’s analysis. Given that the statine moiety is an established pharmacophore known to inhibit aspartic proteases, phormidepistatin was evaluated against cathepsin D and displayed limited activity. With 1 containing a statine-like moiety, we sought to assess the distribution of this γ-amino acid within the phylum Cyanobacteria. In-depth MS/MS analysis identified the presence of phormidepistatin in cf. Phormidium sp. UIC 10045 and cf. Trichormus sp. UIC 10039. A structure database search identified 33 known cyanobacterial metabolites containing a statine or statine-like amino acid and, along with phormidepistatin, were grouped into 10 distinct compound classes. A phylogenetic tree was built comprising all cyanobacteria with established 16S rRNA sequences known to produce statine or statine-like-containing compound classes. This analysis suggests the incorporation of the γ-amino acid into secondary metabolites is taxonomically widespread within the phylum. Overall, it is our assessment that cyanobacteria are a potential source for statine or statine-like-containing compounds.
- 27 July 2021
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 84 (8) , 2256-2264
Phormidepistatin from the Cyanobacterium UIC 10484: Assessing the Phylogenetic Distribution of the Statine Pharmacophore
A new linear lipopeptide, phormidepistatin (1), containing an epi-statine amino acid was isolated from cf. Phormidium sp. strain UIC 10484. The planar structure was elucidated by 1D and 2D NMR experimentation. The relative configuration was determined by J-based configurational analysis and the absolute configuration by advanced Marfey’s analysis. Given that the statine moiety is an established pharmacophore known to inhibit aspartic proteases, phormidepistatin was evaluated against cathepsin D and displayed limited activity. With 1 containing a statine-like moiety, we sought to assess the distribution of this γ-amino acid within the phylum Cyanobacteria. In-depth MS/MS analysis identified the presence of phormidepistatin in cf. Phormidium sp. UIC 10045 and cf. Trichormus sp. UIC 10039. A structure database search identified 33 known cyanobacterial metabolites containing a statine or statine-like amino acid and, along with phormidepistatin, were grouped into 10 distinct compound classes. A phylogenetic tree was built comprising all cyanobacteria with established 16S rRNA sequences known to produce statine or statine-like-containing compound classes. This analysis suggests the incorporation of the γ-amino acid into secondary metabolites is taxonomically widespread within the phylum. Overall, it is our assessment that cyanobacteria are a potential source for statine or statine-like-containing compounds.
- 31 March 2020
- Published by Springer Nature in The Journal of Antibiotics
- Vol. 73 (8) , 526-533
Laxaphycins B5 and B6 from the cultured cyanobacterium UIC 10484
Two laxaphycin type-B cyclic dodecapeptides, laxaphycins B5 and B6, were obtained from UIC 10484, a freshwater cf. Phormidium sp. Analysis using the 16S rRNA sequence found UIC 10484 to clade with UIC 10045, a known laxaphycin type-A and -B producer, and MS/MS analysis revealed the presence of two novel laxaphycin type-B compounds. The structures of the metabolites were elucidated using 2D NMR and MS/MS. The absolute configurations of the amino acids were determined by advanced Marfey’s analysis. Both metabolites were evaluated against the same three cancer cell lines. The IC50 of both laxaphycins B5 and B6 was near 1 μM against breast cancer MDA-MB-231, melanoma MDA-MB-435, and ovarian cancer OVCAR3 cell lines.
- 31 March 2020
- Published by Springer Nature in The Journal of Antibiotics
- Vol. 73 (8) , 526-533
Laxaphycins B5 and B6 from the cultured cyanobacterium UIC 10484
Two laxaphycin type-B cyclic dodecapeptides, laxaphycins B5 and B6, were obtained from UIC 10484, a freshwater cf. Phormidium sp. Analysis using the 16S rRNA sequence found UIC 10484 to clade with UIC 10045, a known laxaphycin type-A and -B producer, and MS/MS analysis revealed the presence of two novel laxaphycin type-B compounds. The structures of the metabolites were elucidated using 2D NMR and MS/MS. The absolute configurations of the amino acids were determined by advanced Marfey’s analysis. Both metabolites were evaluated against the same three cancer cell lines. The IC50 of both laxaphycins B5 and B6 was near 1 μM against breast cancer MDA-MB-231, melanoma MDA-MB-435, and ovarian cancer OVCAR3 cell lines.